戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ection, a related virus, can be treated with convalescent-phase serum.
2 acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decrea
3 Antibody to rDR2/Fic or passively protective convalescent-phase serum blocked IbpA-mediated cytotoxic
4                                              Convalescent-phase serum collected from a GII.4.2009 out
5 eutralization of GI VLPs was demonstrated by convalescent-phase serum cross-blockade of GI VLP-HBGA i
6                                              Convalescent-phase serum from a patient with an active G
7 era from infected/vaccinated guinea pigs and convalescent-phase serum from human patients who had rec
8                                              Convalescent-phase serum from humans following clinical
9  1996 using a large collection of acute- and convalescent-phase serum pairs (n = 298) collected from
10  to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-tra
11 confirm acute infections in the absence of a convalescent-phase serum sample, and provide the high-th
12 f these patients without the submission of a convalescent-phase serum sample.
13  Euroimmun, and Ortho-Clinical IgG assays in convalescent-phase serum samples collected more than 14
14 sis--specific 31-kD antigen were detected in convalescent-phase serum samples from 11 patients.
15  The geometric mean titers of the acute- and convalescent-phase serum samples measured by IFA were 1:
16                                   Acute- and convalescent-phase serum samples obtained from 42 patien
17                                     All nine convalescent-phase serum samples tested had neutralizing
18 ing titer were observed when acute-phase and convalescent-phase serum samples were compared (168 [44%
19          Our findings were validated using a convalescent-phase serum specimen from a patient infecte
20  LD-endemic areas to provide acute- (S1) and convalescent-phase serum specimens (S2).
21 ced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50%